Antiplatelet Agent-Related Peptic Ulcer Disease |
Young Woon Chang |
Department of Gastroenterology, Kyung Hee University College of Medicine, Seoul, Korea |
항혈소판제에 의한 소화성 궤양 |
장영운 |
경희대학교 의과대학 소화기내과 |
Correspondence:
Young Woon Chang, Tel: +82-2-958-1660, Fax: +82-2-968-1848, Email: cywgi@chollian.net |
|
|
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Abstract |
Antiplatelet therapies have been widely used to prevent cardiovascular diseases. However, antiplatelet agents cause gastrointestinal (GI) damage and are associated with a greater risk of gastroduodenal ulcers and life-threatening ulcer complications. The first step to reduce the GI risk of antiplatelet therapy is to assess whether the patient requires continuous antiplatelet therapy. The second step is to eliminate risk factors that may place the patient at greater GI risk such as Helicobacter pylori infection, NSAID use, steroid ingestion, and smoking. Continuous aspirin therapy plus a powerful proton pump inhibitor (PPI) is the choice of treatment for antiplatelet-related peptic ulcers. The risk of cardiovascular complications and risk of gastric complication using antiplatelet agents should be evaluated individually. (Korean J Med 2014;86:673-677) |
Key Words:
Antiplatelet-related peptic ulcer; Proton pump inhibitor |
주제어:
항혈소판제에 의한 궤양; 프로톤 펌프 저해제 |